Drugs / CCX354
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01027728 | Dec 2009 → Jul 2010 | rheumatoid arthritis | Amgen | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01242917 | Sep 2010 → Jul 2011 | rheumatoid arthritis | Amgen | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CCX354 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4444976 ↗ |
| Known as | CCX354-C | “The purpose of this study is to evaluate the safety and tolerability of multiple oral doses of CCX354-C at a number of dose levels in subjects with stable rheumatoid arthritis (RA).” NCT01027728 ↗ |
| Known as | GSK-2941266 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4444976 ↗ |
| Action | Inhibit | “C-C chemokine receptor type 1 antagonist” CHEMBL4444976 ↗ |
| Modality | Small molecule | — CHEMBL4444976 ↗ |
| Route | Oral | “multiple oral doses” NCT01027728 ↗ |
| Target | CCR1 | “C-C chemokine receptor type 1 antagonist” CHEMBL4444976 ↗ |